Batakrishna Jana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Batakrishna Jana has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Abhijit Saha
Department of Chemistry SRM Institute of Science and Technology Kattankulathur Tamil Nadu 603203 India
2 shared publications - Debmalya Bhunia
Cold Spring Harbor Laboratory, 1 Bungtown Rd, Cold Spring Harbor, NY 11724, USA
2 shared publications - Prasenjit Mondal
Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, United States
2 shared publications - Prashant Kurkute
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, Mumbai-400056, India
2 shared publications - Saswat Mohapatra
Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute Los Angeles CA USA
2 shared publications - Subhajit Ghosh
Department of Radiation Oncology
2 shared publications
Latest Publications
Photoinduced Charge Transfer between Metal Halide Perovskite and Ru‐Polypyridyl Complexes Toward Biocatalytic Reactions
Vacancy‐ordered Bi‐based perovskites, such as Cs 3 Bi 2 Br 9 (CBB), exhibit relatively high Lewis acidity due to Bi 3 ⁺ centers, providing favorable acidic sites for organic transformations. Coupled with their tuneable optoelectronic properties, these features render CBB an efficient photocatalyst for various acid‐catalyzed reactions. In this study, CBB is conjugated with a classical Ru(II)‐polypyridyl photosensitizer (RuPS) to form a hybrid material, CBB/RuPS, capable of facilitating thermodynamically favourable inner‐sphere electron transfer. This process yields the reduced RuPS radical anion (RuPS •− ) and a hole (h⁺) in the oxidized CBB species. Ultrafast charge recombination is suppressed through an efficient extraction of e− and h⁺ by the redox‐active substrates, generating spatially separated redox centres that drive tandem oxidative and reductive transformations. Comprehensive spectroscopic, microscopic, and analytical studies confirm the successful formation of the CBB/RuPS hybrid. Steady‐state and time‐resolved spectroscopic analyses reveal the thermodynamic viability of photoinduced electron transfer, with CBB exhibiting a sub‐nanosecond photoluminescence lifetime and electron transfer to RuPS occurring within 200–300 ps. This is evidenced by the appearance of RuPS •− signatures and multiexponential decay kinetics of CBB. Finally, the efficient exciton diffusion in the hybrid system is harnessed for in vitro photo‐biocatalytic reactions, enabling selective oxidation and reduction of substrates, demonstrating potential cytotoxicity toward cancer cells via deprivation of NADH/pyruvic acid and in situ generated ROS species.
Photoinduced Charge Transfer between Metal Halide Perovskite and Ru‐Polypyridyl Complexes Toward Biocatalytic Reactions
Vacancy‐ordered Bi‐based perovskites, such as Cs 3 Bi 2 Br 9 (CBB), exhibit relatively high Lewis acidity due to Bi 3 ⁺ centers, providing favorable acidic sites for organic transformations. Coupled with their tuneable optoelectronic properties, these features render CBB an efficient photocatalyst for various acid‐catalyzed reactions. In this study, CBB is conjugated with a classical Ru(II)‐polypyridyl photosensitizer (RuPS) to form a hybrid material, CBB/RuPS, capable of facilitating thermodynamically favourable inner‐sphere electron transfer. This process yields the reduced RuPS radical anion (RuPS •− ) and a hole (h⁺) in the oxidized CBB species. Ultrafast charge recombination is suppressed through an efficient extraction of e− and h⁺ by the redox‐active substrates, generating spatially separated redox centres that drive tandem oxidative and reductive transformations. Comprehensive spectroscopic, microscopic, and analytical studies confirm the successful formation of the CBB/RuPS hybrid. Steady‐state and time‐resolved spectroscopic analyses reveal the thermodynamic viability of photoinduced electron transfer, with CBB exhibiting a sub‐nanosecond photoluminescence lifetime and electron transfer to RuPS occurring within 200–300 ps. This is evidenced by the appearance of RuPS •− signatures and multiexponential decay kinetics of CBB. Finally, the efficient exciton diffusion in the hybrid system is harnessed for in vitro photo‐biocatalytic reactions, enabling selective oxidation and reduction of substrates, demonstrating potential cytotoxicity toward cancer cells via deprivation of NADH/pyruvic acid and in situ generated ROS species.
- Open Access
- 27 September 2021
- Published by Wiley in ChemBioChem
- Vol. 22 (24) , 3391-3397
Mitochondrial Membrane Disrupting Molecules for Selective Killing of Senescent Cells
Cellular senescence, a stable form of cell cycle arrest, facilitates protection from tumorigenesis and aids in tissue repair as they accumulate in the body at an early age. However, long‐term retention of senescent cells causes inflammation, aging of the tissue, and progression of deadly diseases such as obesity, diabetes, and atherosclerosis. Various attempts have been made to achieve selective elimination of senescent cells from the body, yet little has been explored in designing the mitochondria‐targeted senolytic agent. Many characteristics of senescence are associated with mitochondria. Here we have designed a library of alkyl‐monoquaternary ammonium‐triphenyl phosphine (TPP) and alkyl‐diquaternary ammonium‐TPP of varying alkyl chain lengths, which target the mitochondria; we also studied their senolytic properties. It was observed that the alkyl‐diquaternary ammonium‐TPP with the longest chain length induced apoptosis in senescent cells selectively via an increase of reactive oxygen species (ROS) and mitochondrial membrane disruption. This study demonstrates that mitochondria could be a potential target for designing new small molecules as senolytic agents for the treatment of a variety of dysfunctions associated with pathological aging.
- 27 September 2021
- Published by Wiley in ChemBioChem
- Vol. 22 (24) , 3391-3397
Open AccessMitochondrial Membrane Disrupting Molecules for Selective Killing of Senescent Cells
Cellular senescence, a stable form of cell cycle arrest, facilitates protection from tumorigenesis and aids in tissue repair as they accumulate in the body at an early age. However, long‐term retention of senescent cells causes inflammation, aging of the tissue, and progression of deadly diseases such as obesity, diabetes, and atherosclerosis. Various attempts have been made to achieve selective elimination of senescent cells from the body, yet little has been explored in designing the mitochondria‐targeted senolytic agent. Many characteristics of senescence are associated with mitochondria. Here we have designed a library of alkyl‐monoquaternary ammonium‐triphenyl phosphine (TPP) and alkyl‐diquaternary ammonium‐TPP of varying alkyl chain lengths, which target the mitochondria; we also studied their senolytic properties. It was observed that the alkyl‐diquaternary ammonium‐TPP with the longest chain length induced apoptosis in senescent cells selectively via an increase of reactive oxygen species (ROS) and mitochondrial membrane disruption. This study demonstrates that mitochondria could be a potential target for designing new small molecules as senolytic agents for the treatment of a variety of dysfunctions associated with pathological aging.
- 26 September 2016
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 52 (85) , 12657-12660
Novel tubulin-targeted cell penetrating antimitotic octapeptide
Here, we have discovered an antimitotic cell penetrating octapeptide containing single Arg amino acid.
- 26 September 2016
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 52 (85) , 12657-12660
Novel tubulin-targeted cell penetrating antimitotic octapeptide
Here, we have discovered an antimitotic cell penetrating octapeptide containing single Arg amino acid.
- 9 July 2015
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 6 (8) , 1309-1316
Novel Hexapeptide Interacts with Tubulin and Microtubules, Inhibits Aβ Fibrillation, and Shows Significant Neuroprotection
Herein, we report a novel hexapeptide, derived from activity dependent neuroprotective protein (ADNP), that spontaneously self-assembles to form antiparallel β-sheet structure and produces nanovesicles under physiological conditions. This peptide not only strongly binds with β-tubulin in the taxol binding site but also binds with the microtubule lattice in vitro as well as in intracellular microtubule networks. Interestingly, it shows inhibition of amyloid fibril formation upon co-incubation with Aβ peptide following an interesting mechanistic pathway and excellent neuroprotection in PC12 cells treated with anti-nerve growth factor (NGF). The potential of this hexapeptide opens up a new paradigm in design and development of novel therapeutics for AD.
- 9 July 2015
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 6 (8) , 1309-1316
Novel Hexapeptide Interacts with Tubulin and Microtubules, Inhibits Aβ Fibrillation, and Shows Significant Neuroprotection
Herein, we report a novel hexapeptide, derived from activity dependent neuroprotective protein (ADNP), that spontaneously self-assembles to form antiparallel β-sheet structure and produces nanovesicles under physiological conditions. This peptide not only strongly binds with β-tubulin in the taxol binding site but also binds with the microtubule lattice in vitro as well as in intracellular microtubule networks. Interestingly, it shows inhibition of amyloid fibril formation upon co-incubation with Aβ peptide following an interesting mechanistic pathway and excellent neuroprotection in PC12 cells treated with anti-nerve growth factor (NGF). The potential of this hexapeptide opens up a new paradigm in design and development of novel therapeutics for AD.